We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

Regeneron hosted a celebration to recognize the achievements of the 17 students selected as the Westchester 2025 Regeneron Science Talent Search Scholars. Beginning in 1942, the contest […] ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index ...

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Follow us ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2 ...

Physician-scientist led biotech Regeneron will be responsible for funding preclinical and clinical development and commercialisation activities, while oncology-focused biopharma CytomX will ...